Moreover, treatment of TPC-1 and BCPAP cells for 24 h with trametinib, a MEK inhibitor which was shown to reduce HMGA2 mRNA expression levels [11], increased TG, TPO and PAX8 mRNA levels (Figure 3b), suggesting that the MAPK pathway induces cell dedifferentiation in papillary thyroid carcinomas through HMGA2. This evidence concerns the gene HMGA2 and differentiated thyroid carcinoma.